Chemical Structure (Imiquimod 01)
Imiquimod
Product Images NDC 52549-4145
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Imiquimod (NDC 52549-4145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Taro Pharmaceutical Industries Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Imiquimod 02)
This appears to be the summary table of a research study evaluating the efficacy of Imiquimod Cream. The study had 209 enrolled participants, out of which 109 completed the treatment, and 36 were deemed clear. 39 participants completed a 12-week follow-up and remained clear. The study mentions withdrawals and subjects lost to follow-up or experienced recurrences. The study does not provide information on the nature of the treatment or the intended outcomes.*
Principal Display Panel (24 Packet Carton)
This is a medication containing Imiquimod for dermatologic use only. The package contains a single-use packet that contains Imiquimod 5% along with inactive ingredients such as benzy alcohol, cetyl alcohol, glycerin, and xanthan gum. The medication should be stored at 4-25°C and kept out of reach of children. There is additional information regarding dosage recommendations on the accompanying insert. Made by Taro Pharmaceutical Industries Ltd in Halfa By, Isael 26110, and distributed by Tro Pharmaceuticals USA, Inc. in Hauthorne, NY 10532. NDC 51672-4145-5. Not for ophthalmic use. The net weigh per packet is 0.25g and per box is 6.9g.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
